CompanyHealthAi
Excelsior Sciences
Excelsior Sciences is a New York City biotech building 'machine-native chemistry' - a way to make small molecules that machines can execute and AI can learn from. Its proprietary smart bloccs platform turns drug synthesis into a modular, automation-friendly, iterative process, closing the loop between AI-driven discovery and real-world manufacturing. Founded in 2024 and spun out of Deerfield Management, the company raised $95M in late 2025 to scale the platform and reshore U.S. drug discovery and production.
2024Founded
New YorkHQ
$25,000,000Grant (Empire State Development)
biotechnologysmall-moleculedrug-discoveryautomated-chemistrymachine-native-chemistrysmart-bloccs